Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danoprevir/ritonavir-based combination therapy in prior peginterferon/ribavirin failure for chronic hepatitis C genotype 1
2010-019585-90Phase 2Completed
- Sponsor
- Roche
- Start
- Feb 2011
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of danoprevir, mericitabine, interferon alfa, ribavirin and ritonavir in hepatitis C virus infection (3 arms), sponsored by Roche. Primary endpoint: SVR-24 according to planned treatment duration. Started Feb 2011; status: completed.
02
Drugs
danoprevirmericitabineinterferon alfaribavirinritonavir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2010-019585-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019585-90.